Drug Profile
PS 248288
Alternative Names: PS248288Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pharmacopeia
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Metabolic-disorders in USA
- 09 Feb 2009 Phase-I clinical trials in Metabolic disorders in USA (unspecified route)